LQDA - Earnings call transcript Q3 2024

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good morning, and welcome, everyone, to Liquidia Corporation Third Quarter 2024 Financial Results and Corporate Update Conference Call. My name is Michelle, and I will be your conference operator today. [Operator Instructions] I would like to remind everyone that this conference call is being recorded.

I would now like to hand the conference over to Jason Adair, Chief Business Officer. Please go ahead.

Jason Adair

Michelle. you, Thank to Third pleasure Call. today the to It's XXXX welcome Financial Corporation Quarter Update Results Liquidia my everybody and Corporate

Joining Counsel, CFO, Chief Chief the Chief Commercial Officer, are Dr. Moomaw; Saggar; call Jeffs; and Scott Roger General Dr. Executive Rajeev Operating Schundler. Kaseta; Michael Officer, and Officer, Chief Rusty Medical Officer today

the statements may results, we are call. company's as including those from statements, this begin, contain will expressed subject forward-looking information achievements. and/or please Before performance financial be regarding or future note uncertainties, to performance known and on different unaudited unknown cause future These performance risks and call well any forward-looking materially results or that as implied which today's future results our conference and actual or to statements

discussion accessed including and the our with of risk information, documents the be factors, Securities to additional a can please on company's which our refer For filed website. Exchange Commission, detailed

prepared Roger to like questions. turn now our for call open I'd which over your the to he the will for remarks, call after

Roger Jeffs

morning, be you speaking We're to Good today. with pleased everyone.

made patients. significant occur the to of months' over on exclusivity seeking or expiration just for TYVASO XXXX, approval in last and we now few progress X could time. have of a final the With YUTREPIA PAH DPI's clinical both sight Final months, approval clear PH-ILD line the of following May XX,

September against longer to Court's serve, the met FDA requirements confirmed and And tentatively the has that Supreme no amended to of legal asserted been the with approval that wins originally the exhausted, the X have provide the approved clinical second, expiration included proper YUTREPIA process X underpinned us, the any PH-ILD, of Critical PAH these that patents for and commercialization for to decision DPI's to YUTREPIA. exclusivity. therefore, respect deny was fully the the significant to regulatory determine pending for first, to and TYVASO label add following: we NDA patents the with had PH-ILD in the impediment milestone

cited blocking earlier are clinical sole FDA exclusivity a in or Rusty to will of DPI, of mentioned, minute. May speak is lawsuit 'XX we the the our in this new lawsuit granted that YUTREPIA TYVASO was expire by if in As which that investigation against the the will approval successful specifically item final more is about FDA.

the compelling future. In now we PH-ILD clinical demonstrate LXXX sustained next-generation advancing release of clinical patients prospectively feel program, active and our programs and options advancing treprostinil us productive to that of inhaler, in remain PAH patients, and as value LXXX. have YUTREPIA gives treatment treat developed differentiated a and in for both firm, combination delivery We portfolio the of in as our YUTREPIA PH-ILD of the to we the well

On this we amending relationship a North the related license agreement our quarter, our in have EU to Pharmosa LXXX, include of other territories with expanded and front, America. outside business with respect to

small, rights that excitement or programs on proprietary We portable to is will prospective building of LXXX both and iPhone. Rajeev breath-actuated with a entered have to clinical device within a community agreement license the progress of to an also next-generation studies. Pharmosa based in nebulizers the share administration of nebulizer, the size secure into speak our

balance to especially, in the treatment the determination doubt call. long capital, change the will closed the have pulmonary that in patients team, near products, balance have our vision we and in my hypertension several sheet landscape and of mind the the the term. we in later But simultaneous having sheet, Mike strengthened on offer more our is no there insight finally, And financings also September.

to With that, I Rusty some share will ask details. more

Russell Schundler

Roger. you, Thank

FDA's DPI, grant the we which new we briefly of to YUTREPIA. to TYVASO lightly. the FDA's new August, took challenged TYVASO we the that in investigation decision has that previously award INCREASE and filed prior note lawsuit a in final of This studied not As PH-ILD of not is based safety delayed clinical And decision efficacy trial, investigation nebulized challenging mentioned, did a which PH-ILD was nebulized I on approval the exclusivity Roger patients. TYVASO clinical exclusivity in to

This Unlike trial the this bolstered exclusivity of belief clinical study, not decision the for FDA's own by we XXXX. be INCREASE to upon in initial do approved which DPI type first was not BREATH based, to when it trial, believe exclusivity which the TYVASO any clinical trial was clinical the is can the new granted. grant exclusivities is

the the be reason, the believe to the this and be liquidity for anticipation DPI scheduled agreed TYVASO We expedited to immediately. YUTREPIA for XXXX. an in should market have to X, XX, expiration to benefit regardless we FDA XXXX. exclusivity vacated, of that December of schedule the our of motions summary respective delay And For briefing should can continue of FDA's hearing on the allowed nothing patients and the a for bring on judgment decision lawsuit though, on May of outcome

that the lawsuit then dismissed the by challenging in previously lawsuit the United are amendment of the brought, appropriateness label. Therapeutics add of YUTREPIA the FDA Therapeutics were voluntarily our United the February. part against to essentially initiated FDA, against to back These PH-ILD in again As cross-claims and exact same they has the filed claims

YUTREPIA believe have when issued the tentative with to indications PH-ILD, a these liquidity amended that agreed for cross-claims for NDA continue position approval properly have August. no YUTREPIA both merit, they FDA that to that the add in We in and

with any regarding now initially successfully dosing the leaves Therapeutics against Those label. in 'XXX decisions, United sole concluded infringe any patients the by in assert United continuing Therapeutics. TYVASO Roger, by PH-ILD of the we us further appeals with asserted are that are cover that treatment of not just patents the the the patent to patent subject do any against This of valid TYVASO we X 'XXX claims final. Finally, patent and were is that as to accordance now X patents, litigation as the noted the Liquidia. have not generally regimen

of art including multiple positive 'XXX considerable the the prior review teaches patent that have decade PH-ILD to the prior from described treating noted priority peer and treatment TYVASO, the the As previously, that for patients date TYVASO. publications patent 'XXX results in with is there with patients PH-ILD we

denied disclosed, that to the briefly resolving patent of preliminary time. as of injunction on patients for United sought patent YUTREPIA block court. the by scheduled and PH-ILD XXXX, of look a validity and launch June the Also, Therapeutics for we treatment Trial based the at is forward of the 'XXX now 'XXX is the to

turn call to to summarize over the like the I'd that, date. Rajeev progress clinical With to to

Rajeev Saggar

on Rusty. continued in Thanks, I'm programs and Liquidia's momentum excited the to YUTREPIA with positive report clinical LXXX.

open-label study, which the efficacy tolerability the on of update an provide me and is YUTREPIA in patients safety, let ASCENT evaluating with First, PH-ILD.

III is first tolerability the in quarter INSPIRE from regards XX of date, track during of The enrolled observations the We the us patients from pivotal PAH Phase of highly patients, And XXXX. our with firmly titratability. which PH-ILD complete the preliminary in data to is the of enrollment active. consistent in have study sites with To doubled patients. generally quarter, now number sites we it in to have on keeps ASCENT and clinical emerging past XX plant now the over encouraging X/X the study

times weeks powder X patients and of patients inhaler, with average treatment low effort able reaching who formulation, XXX our micrograms, the ] X have week by dry coupled to [ YUTREPIA with to micrograms dose As our print of almost completed an a anticipated, of titrate have X. with been tolerate XXX.X X/X day

and up is observed is the practice. used than in week in weeks comparable INCREASE Xx dosing nebulized This the at study typically clinical X TYVASO administered both to study XX in through doses ASCENT with the what higher

After continued we completes distance next While including higher, we titrate week data in the trends positive when still the efficacy forward remain it set year. full very reporting early, in patient-reported key the and X, patients have study to and the noted walk from by to change look X-minute encouraged endpoints, outcomes.

now formulation our focused daily, attention our in liposomal placebo-controlled PH-ILD solely our turning called, study Phase initiating suspension on global LXXX, Now treprostinil twice we III to delivered RESPIRE. are sustained-release

trial to data we open-label with patients, observed study this Given total stop in enrollment safety XX to U.S. very PH-ILD a and date to of PAH and the decided tolerability in favorable have in well the is which tolerated, daily, continues with Xx INCREASE than twice study. approximately reaching micrograms XXX enrolled. LXXX of some doses patients be dose of patients comparable our in higher the maximum administered TYVASO

is shared to X As Roger on to design in this less of of study, minutes. initiation the also have breath-actuated push XXXX. and study device rechargeable, session of more rights device near that will the be into details pivotal capable pivotal We've in nebulizer will doses future. delivering LXXX streamlined use decided our which of the X we to half the first than new mentioned, inhalation handheld, a More secured

the the Kaseta call Mike I to the for would now to to like review financial quarter. third Mike? performance pass

Michael Kaseta

potential you, Liquidia good everyone. sheet YUTREPIA, our our To the first approval. executing remain XXXX hand to simultaneously to XXXX YUTREPIA. in as more I'm of launch receive cash to We company pleased well final to culminating Rajeev, September. as that further the that the with in Thank soon product, on the of is say into in million preparedness, FDA by strength announced million third $XXX.X objectives third corporate and balance positioned $XXX morning, our as and launch even quarter its quarter prepared support transactions X we in we achieve approximately ended brought on added well

quarter release. in I third briefly will address press now today's financial found our results

XXXX First, Revenue promotion quarter revenue of ] million higher in compared in [ injection. was $X.X to related third as same with impact prior compared quantities treprostinil $X.X was $X.X our primarily same the the to the of The to primarily to Sandoz for quarter year due the with agreement period the million the million current increase in year. commercialize of XXXX. sales

mentioned the Research the development from third quarter in offset prior of promotion expenses revenue same during at related $X.X development million year. of and quarter primarily reflecting in the increase or costs in LXXX increase prior our $X.X $X.X million same related the 'XX research million million revenue and in the year was of consistent million to to including a expenses personnel expenses increase to primarily trial, increased to a to ASCENT $X.X million expenses, expenses, lower the the expensing impact program XX% in increase of million $X.X due $X.X $X.X remained compared related the The related and headcount, compensation $XX.X $X.X YUTREPIA manufacturing force quarter of million were commercial to in quarter clinical for activities, the inventory compared a XXXX for stock-based including XXXX. sales due with XXXX. our YUTREPIA by earlier. was expansion to third fourth increase The in quarter of Cost agreement XXXX. for million Cost

Moving and in in 'XX, our of in for including general compensation, the commercialization administrative personnel The legal on million sales was potential $XX.X relating third due increase million headcount litigation expenses. $X.X were stock-based driven million to same quarter primarily preparation increase of expenses, YUTREPIA. a million XX% $X.X expansion by our force to $X.X in and XXXX. increase the YUTREPIA-related quarter a ongoing increase fourth million to quarter of or of in XXXX commercial They to compared expenses for higher a the $XX.X and in in $X.X million fees

share loss we compared $X.XX for net or X months months XXXX, summary, basic diluted loss the million In of ended $X.XX diluted $XX.X a X September million XX, for September the or per and XX, share $XX.X basic per ended to of a incurred and XXXX. net

With to to -- that, over now call to back the like Roger? like Roger. turn I'd

Roger Jeffs

and please. for Rusty to Operator, insights. sharing those for Thank you, you, open Mike, Rajeev, I now like questions, thank also call would and the

Operator

question with Instructions] Julian BTIG. come [Operator Our going first from to is Harrison

Julian Harrison

a contemplating wondering hearing? have talk First, that hearing could sense a right how soon about good decision for December. from the regarding And you be of delivered summary can outcomes now I'm the judgment in there? if you're maybe from range you

Roger Jeffs

Nice Rusty, if to please. that, comment you. could hear you on from

Russell Schundler

Julian, for question. the Sure. thanks

any typical response, time set or no that judge, for guidance to rule, advance. any so on So There's it's with hard really as the predict and it's in far point. for judges timing proceedings with give as hard to to deadline line

further proceeding. of far Procedures decision. typical main judge any for the The the for could Act as the judge are the As back outright -- the just or overrule judge range even consideration. those, Administrative could they're outcomes FDA the remand decision of the could all uphold range Obviously, with of outcomes, iterations there X those pathways. And to are but sort the

Julian Harrison

ASCENT the first in Okay. completion very then quickly next Great. year. on expected And great trial, helpful. is to That's hear enrollment quarter

disclosure you what but color be is maybe data missed for to to from the Sorry the disclose great. on Do data at if would plan your a Any data there? it, timing conference? expectation I wondering

Roger Jeffs

question. Yes. the Thanks you again timing for of the could Rajeev, data on the comment disclosure. if

Rajeev Saggar

Julian. Good to hear Thanks, from you. Yes.

So we -- study. as you an know, open-label is this

look up. to of the with -- a at continue coming data and We data sets will submit frequency, certain every congresses we various to the amount

have we data to set Congress. data if first then So half anticipate accepted, submitted And of XXXX. a that of showcasing in we the

Roger Jeffs

Great. that, persistence that also, And you're some it dose that within going durability to of the that, disclose -- impact YUTREPIA, particularly the Julian, dose I important quickly Rajeev. to on thing of to of the Thanks then would for terms critically value as outcomes. to And ability subset. dose, see the patient think that to is differentiates I and data driving in treatment relates information add clinical the of we'll get

competitive can tolerability, have think been when this data low-resistance you DPI, which So I for the titratability is we put set, at a then out and device, that TYVASO the data that all persistence, point. think to there of differentiated look if to we show greater I the sets through some will durability, particularly lead patient-friendly, think molecule,

Operator

Gerberry going is of with from line Jason question next to Our the come BofA.

Jason Gerberry

A for me. couple

that about Just access have the helpful. we you Or be period? thinking can -- you think any on that early provide YUTREPIA should pretty color as friction just confidence you'll you access your of wondering points side launch in level if as would the there parity about launch coverage be the Any launch, product?

generally running? ILD And got I the plan not for is framework right, terms year, a good at we then study but providing that formalized, on of of to to in is the increase LXXX don't if update, about know the be that should next pivotal go I type design direct think a if you'd

Roger Jeffs

Great.

to terms for I'll one. of that first the speak to second And in LXXX plan Rajeev ask pivotal the question, think, question, timing. I answer So coverage on and the Mike can access,

Michael Kaseta

for prepared We've the thanks in of been kind about with we to Relating question. brings. to to YUTREPIA engaging YUTREPIA Jason, Yes, since proposition approval value we've been released the XXXX. launch payers access, that talk

that and obtain. As a feel our of we to that we're conversations, we're able result think going that those obviously something confident be goal I access to confident is

we'll those working towards get we as are conversations, as close continue access but have But to closer we to as launch, having to a launch possible.

Roger Jeffs

Mike. Thanks,

then maybe our Rajeev, study? is So you can similar speak And size we're to terms design to how INCREASE timing? in thinking of sample and what kind about the of

Rajeev Saggar

Jason. Yes, sure. Thanks,

I tolerability gave the the in us our study So that confidence here the I the think dosing as really our remarks, and open-label again, safety is prepared key and for LXXX profile. about stated

I compliance LXXX think terms for of game-changing quite in the twice-a-day terms format in here the and is patients, performance. of

for the the patient. The is that to one next the step is nebulizer really ensure right

key absolutely chosen have we that is nebulizer will nebulizer motif the drug any deposition. ensure think for I that the

we've think target. going that's patients performance in We So our for to hit with that maximize LXXX PH-ILD. we believe

to sorry, the INCREASE as In using overall important a note. is replicable I format, the patient study regards trial -- to think

understanding I patients can these to certain time distance X-minute think within walk periods be improve critical. is that going

we that I rough use estimate. So as think a

somewhere between global time sample an in overall, that be I XXX ensure be is to can success frame. patients. is going Again, In sample study. size XXX multiple terms think achieve in the will we've a size of we countries this said the appropriate overall to enrolled to This

Roger Jeffs

only hours, Xx, which should the that be is diminish benefit. that cough effects thing reduced which by the further AUC upper add in because we're higher with and we XX is means I'd should retaining in doses, the to Right. the over airway, even to higher And CMAX Jason, that, throat particular, irritation the then to off-target should able titrate to lead LXXX,

we'll but expectation my to So holds this going if used of have same assumptions outcome true. in all better power increase, than a that is we're around study the

Operator

Our Scotiabank. to going with come of the line next Harrison is from question Greg

Gregory Harrison

well set ready. launch are looks the pretty preparations and YUTREPIA It like is

ask can especially for development the opportunity time then Can I just respect So to expectations enrollment, global how overall, and us wanted what do you expedite to view ex given you frame with for for you And to this this? lines help about nature LXXX. the U.S.? asset,

Roger Jeffs

Yes, I'll take that one.

it's So I timing think Greg. we always hard when talk to haven't about started,

little things in Rajeev opening predict I So But trial trial 'XX. early. as want to said start a half cautious initiate in of not and sort of here his the we comments, the -- plan the to first be bit too

the XX have the enroll XX-month would and run X to our last take through expectation months then your assimilate data, the And that you them we the it can then months typical file it in, XX X through patient trial It's to say, months. to study, review.

just you're of sort you generalized if put So just X years. in talking start to all that finish, from in together, a sense,

we can that. think beat I

this we're reason to will available. in are from TYVASO I'd DPI i.e., et where TYVASO -- of South Australia, most and say cetera. territories, the come the that is America, U.S. do EU, not the And going enrollment China, ex

development the and a think certainly, is get logistics up So to for challenge. it's positioned We're in it massive done. our effort, of terms I well team

of trials a lot management certainly for experience in these of have We -- sure. experience doing types

in our approval I this get the these we potentially So say I on because for we FDA of I'm to both brand global could will not said partnership. with this unmet that's have provider once as that expanded states PH-ILD. beat we U.S. license we the and need work for didn't additional But maybe is before, a with -- that why goal. the with EMA LXXX and the confident very is will but to patients, and I'm of of the start, serve with out reason the PAH call, line patients we're are with That's The become required. the Pharmosa, the we goal think we'll and agreement time pleased for have massive And study PH-ILD.

with, said, expansion was than to of nebulizer. And also as we came are the The different these the acquisition nebulizers. current very rights next-generation their

nebulizer it, years XX was If about TYVASO you development the ago. think in

It's is an So it's size This a and dated cumbersome. the of bulky breath a that's nebulizer IPhone portable nebulizer. actuated.

of ability to terms to need we and easily. has reliable as patients, through in kinetics precise deliver delivery and shown drugs solution deliver Pharmosa amount and the titrate quite And of that strengths we in very testing, dose its these the exact can to different

everything was going So doing have well, the that we're done spectacularly We FDA reason we you now in why well. up this just just is setting the device. work now, some of delay with ask to to that these have with compatibility for device have final you started patients. of the to get up The then work would is the we to dossier close right drug to going put to have is together device we aren't new terms the and the compatibility delivery file that the but work the provide new that the that we have convince shop

if of about of give to I just to we'll a right. X.X decision, we more that's years timing, progress X pen clarity with sort as you enrollment -- patient in into say again, first from So terms paper, think you just but

Operator

of question with line next Jefferies. Yazdi Kambiz Our the from comes

Kambiz Yazdi

you greater prior of launch. twice your side, XXX-microgram patients inhaler on DPI achieved daily Have AEs maybe For device And with there on supply LXXX, question your been how a study, is? the consistent safety studies? then Can dose? open-label us how remind robust for than -- treprostinil many have the

Roger Jeffs

Yes.

on this that. if about dosing, be if So going Rajeev, what speak we're at supply Mike, able Rajeev? then to the after provide question going talk you could time. to And you can to first forward

Rajeev Saggar

Kambiz. Thanks for sure, the question. Yes,

not twice dosing that in would So patients overwhelming almost greater I to patients mean regards a XXX close all majority say to I achieved -- is achieve have micrograms than profile. of the the of day,

So again, in the be titration early that dosing will profile phase.

for May the the poster at ATS dose exceeded XXXX of shown overall have has in We patients. in median XXX majority our micrograms

think the PAH here in tolerable be leading pointed of the the Roger both I quite So for out, motif I patients LXXX and as these And overall key in populations. this lend I has and itself both think what's liposome to titratability think PH-ILD itself -- process sustained patients. to that's of is the release

and quite we confident the So about profile safety tolerability drug. overall of remain this

Roger Jeffs

we're for at Yes. And breath target in the equivalents, nebulized X solution. think think I to Xx as terms of just a Kambiz, TYVASO therapeutic I

like to airway in respiratory the So the is particles where dry is formulated avoid deposition that again, YUTREPIA YUTREPIA lung lower the a range, AEs. profile, different much delivers upper and end to discrete lower of

CMAX, then diminishes many the the liposomal don't but you sustain the formulation that AEs as Here, CMAX benefit. so can have peak at

in different doses, thing. the and but we and way, a twice-a-day aspect, format. titratability then is does the same So benefit higher critical higher which a retains in allows persistence, It does it for higher think

X all taking a of therapy. builds YUTREPIA, from it twice it therapy a times it good So on a day a has the to of but day by

we're So about program. very that's very, why this excited

device Mike, could about talk if supply? you the

Michael Kaseta

Yes, to Kambiz. to absolutely. Great you, talk

part approval We've to we So we've since been launch the XXXX. early FDA in commercial 'XX. been manufacturing November of of received preparing supply since

the expiration for received. ultra-prepared that we are-- the here marketing upon of launch United a will X-year be We exclusivity

and to May, ready to full in We launch to time we'll frame. capacity the be time at June continue be whenever that comes -- manufacturing

have a very successful launch So very we feel supply. sufficient that have no confident can we with there concern and

Operator

Our next LifeSci the Capital. Cory from comes question Jubinville of with line

Cory Jubinville

the case some in scenario, May this favor, optimistic in guess, an in hearing time tentative more time quickly how relation regard to the to XX us regard X I launch in the can is lines date? assuming would in context the to I in Liquidia's suits? ongoing ruled FDA you guess December, to lines on expedite approval the provide

to launch say launching indications that on in date? PAH now approval PAH unencumbered the you fair in X And that risk May there the patent is at but XX now specifically wait across updates? following do tentative recent in decision it to the is And launch then the to launch? so, totally plans on immediately, is 'XXX anticipate is YUTREPIA the 'XXX given plan PH-ILD, Or the to if there decision,

Roger Jeffs

you Great if mind? Yes. wouldn't question. Rusty,

Russell Schundler

for thanks Cory, question. the Sure.

taking So the questions in the turn. on -- just

it's that because As dependent to answer it's then question on a far fully lawsuit, would the decision FDA highly the of as hard effect is. and of when timing what we decision exactly the the get

if For the a our to just to was we instance, number a of have what exclusivity on exclusivity, assess decision eliminate would other the the versus and narrow to that means label things. as product

So that answer until when know again, it's see the in. we hard decision to to question the comes what it and

we the approval like. the litigation to But FDA standpoint date. if in think of looks that we can on in XXXX. Obviously, that May assess we'll know pursuing the hopes that time the takeaway is the can, that our main And of I at we what sort decision we're ends exclusivity accelerate from have

to against no [indiscernible]. us decision, second to that is correct approval patents is 'XXX on were means Therapeutics the question first against that that deny its dead. asserting the to are X decision are litigation us claims no that United or the with PAH. now related longer FDA As -- There of That you're making that asserted the

all. at at all there's So really encumbering nothing perspective, from PAH our

a we get make risk. As We'll to would approval. to time will make the when think, have said comes as we an whether launch question assessment decision FDA we whether when over at we that's risk, the consistently, final to at launch on time, I

get valid any our at But that said we we've to launch. by point thing products, going landscape the don't don't to say, we're I time I we and hesitate I'd see the infringed other patent and that if patents we consistently, in are look think think is and think and to

discovery we'll again, patent time. that's we're And case. obviously, So 'XXX the through at going in the an make assessment

that But make our art and we substantial 'XXX out as time. that decision said in any certainly belief prior would there weigh I before, that patent, there's predates at heavily the is

Roger Jeffs

have we think time any. I question, one more Operator, for there's if

Operator

Kaplan line And our looks come it question of the is with going Thalman. like next Matt to Ladenburg from

Matthew Kaplan

of questions Most have asked. my been

of year, launching? size Just sales coming near-term to your of the a force, we how commercial about cetera, can next you footprint when opportunity launch of given at the here about should talk of et in terms May you're preparation, market little end in think terms bit

Roger Jeffs

Moomaw, the call. And Commercial, fortunate Yes. to on have we're Scott Chief our

how So talk PH for if kind about around of Scott, calling you force think and we that? both and the about maybe could PH-ILD sales space sizing

Scott Moomaw

Yes, absolutely.

had So team actually. about sales board now we've for on actually the a year

extremely PH. sales multiple launched Our of is PH team the products are rare disease. space from have them and in Most in experienced

about So we're very excited of the them. depth the experience with

PH They're included sized prescribers. -- that, to academic but be as -- from sized treaters, well a ILD it general also the the centers the we've by would and And market. cover entire centers community, large both PH standpoint, they're as mean PH I community in the

pulmonologists there. out there's So

in PH prescribe medications, in currently but PH-ILD their the have don't We offices. certainly patients pool

forward to And sized those either them. of so will our help that into sales get And able a aware PH-ILD. them PH-ILD, into be we've be well, them right, treat willing be or time center patients to then force the those is offices treat if as to diagnosed

targets So address X,XXX X,XXX we think probably We're in there the that sized are to market. to entire about market.

We deep well. in can focused key PH umbrella, we very commercial account as team there also largest, some and centers, are have they centers, and have medical key pieces other a so the as place, such under who the are go we on the most directors, academic that of completely

excited. get we're let and want really just folks to these We to loose. So May

Roger Jeffs

Great. Thanks, Scott.

day So launch. of as you can from hear, we're going voice to share have of significant the

question believe another I there's take? So we that can operator,

Operator

Deschner Ryan come the of line Our James. from last going question is to with Raymond

Ryan Deschner

I if of, you latest I Where the used this detail us a could its something party was terms nebulizer is nebulizer more And is on commercial the next-generation in Pharmosa to nebulizer that's guess, wondering that's development? agreement. currently a own little the give with products?

Roger Jeffs

Yes. I'll answer that quickly.

So own of this looking that. We're secure rights have it's think, to. at nebulizer that a we I our IP to proprietary Ryan, some time, exclusive around

really specifically we're to is to going the trial. what through not use So discuss the we're that nebulizer going

think Certainly, dosing an But described good disclose we'll need. in of coming to important -- we drug that Rajeev the and that quarters, the delivery that's highly precise you. I the portable aspects the breath-actuated, very at it, rechargeable, iPhone-sized nebulizer it's that in nicely of precise aspects the

quarters. I that you can't provide information give at coming I'm this So in we'll more but time, sorry, the

Operator

And I to turn for Jeffs would now closing over remarks. like the conference back Roger any to

Roger Jeffs

and to very look forward that launch questions we to really Well, to coming march advance Thank providing YUTREPIA. of the continue cover further our It's analysts we pleasing the everyone. appreciate Great. have in the -- towards we updates many morning. you, as so questions, this quarters asking

Operator

conference today's participating. concludes for Thank This you call.

You disconnect. may now

Liquidia (LQDA) 13 Nov 242024 Q3 Earnings call transcript